. Author manuscript; available in PMC: 2023 Apr 1.

Published in final edited form as: J Pediatr Gastroenterol Nutr. 2021 Dec 14;74(4):495–502. doi: 10.1097/MPG.0000000000003371

TABLE 3.

Comparison between the equation group and the validation group of subjects with pediatric NAFLD

Variables	Equation group (n=344)	Validation group (n=110)	P value
Age	15 (12, 16)	14 (12, 17)	0.867
Sex, male; n (%)	232 (67%)	80 (73%)	0.298
Ethnicity; n (%)			0.057
White, Hispanic	69 (20%)	32 (29%)
Non-Hispanic	275 (80%)	78 (71%) (80%)
Type 2 diabetes, n (%)	26 (7.6%)	6 (5.5%)	0.453
Medications
Insulin, n (%)	14 (4%)	1 (1%)	0.106
Metformin, n (%)	87 (25%)	25 (23%)	0.587
Vitamin E, n (%)	22 (6%)	8 (7%)	0.747
Statin, n (%)	9 (3%)	2 (2%)	0.636
BMI (kg/m²)	36 (32, 41)	35 (32, 40)	0.100
z score	2.5 (2.2, 2.7)	2.4 (2.2, 2.7)	0.463

Data are presented as medians (ranges) or n (%). BMI = body mass index; NAFLD = non-alcoholic fatty liver disease.